These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8205258)

  • 21. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
    McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
    Parkinson C; Drake WM; Roberts ME; Meeran K; Besser GM; Trainer PJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1797-804. PubMed ID: 11932320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study.
    Colao A; Auriemma RS; Galdiero M; Cappabianca P; Cavallo LM; Esposito F; Grasso LF; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Feb; 94(2):528-37. PubMed ID: 19001517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.
    Helseth R; Carlsen SM; Bollerslev J; Svartberg J; Øksnes M; Skeie S; Fougner SL
    Endocrine; 2016 Feb; 51(2):298-307. PubMed ID: 26179177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity.
    Bertoli A; Magnaterra R; Borboni P; Marini MA; Barini A; Fusco A; Bollea MR
    Horm Res; 1998; 49(1):17-21. PubMed ID: 9438780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular effects of the somatostatin analog octreotide in acromegaly.
    Chanson P; Timsit J; Masquet C; Warnet A; Guillausseau PJ; Birman P; Harris AG; Lubetzki J
    Ann Intern Med; 1990 Dec; 113(12):921-5. PubMed ID: 2240917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
    Fredstorp L; Werner S
    J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report.
    Atkinson AB; McKnight JA; McCance DR; Bell PM
    Horm Res; 1990; 33 Suppl 1():7-11; discussion 11-2. PubMed ID: 2358295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.